clinical trial · NCT06611163
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Moderate to Severe Genital PsoriasisTildrakizumab 100 mgPlacebo
brief summary
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
started
Mar 21, 2025
primary completion
Jan 21, 2026
completion
Feb 1, 2027
last updated
Mar 25, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol